These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 17699252)

  • 1. Septicemia in patients with ESRD is associated with decreased hematocrit and increased use of erythropoietin.
    Nissenson AR; Dylan ML; Griffiths RI; Yu HT; Dubois RW
    Clin J Am Soc Nephrol; 2006 May; 1(3):505-10. PubMed ID: 17699252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of parathyroidectomy on anemia and erythropoietin dosing in end-stage renal disease patients with hyperparathyroidism.
    Trunzo JA; McHenry CR; Schulak JA; Wilhelm SM
    Surgery; 2008 Dec; 144(6):915-8; discussion 919. PubMed ID: 19040997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. r.hu-erythropoietin (EPO) treatment of pre-ESRD patients slows the rate of progression of renal decline.
    Tapolyai M; Kadomatsu S; Perera-Chong M
    BMC Nephrol; 2003 Jun; 4():3. PubMed ID: 12809563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and economic outcomes of Staphylococcus aureus septicemia in ESRD patients receiving hemodialysis.
    Nissenson AR; Dylan ML; Griffiths RI; Yu HT; Dean BB; Danese MD; Dubois RW
    Am J Kidney Dis; 2005 Aug; 46(2):301-8. PubMed ID: 16112049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of recombinant human erythropoietin (rHu-EPO) on anemia and selected biochemical parameters in patients in the pre-dialysis period].
    Sułowicz W; Drozdz M; Hanicki Z; Kraśniak A; Kuźniewski M
    Przegl Lek; 1992; 49(1-2):50-3. PubMed ID: 1455007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenging the validity of the EPO index.
    Kaysen GA; Müller HG; Ding J; Chertow GM
    Am J Kidney Dis; 2006 Jan; 47(1):166. PubMed ID: 16377397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atorvastatin increases erythropoietin-stimulating agent hyporesponsiveness in maintenance hemodialysis patients: role of anti-inflammation effects.
    Chiang CK; Yang SY; Peng YS; Hsu SP; Pai MF; Huang JW; Hung KY; Wu KD
    Am J Nephrol; 2009; 29(5):392-7. PubMed ID: 18974640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can acidosis and hyperphosphataemia result in increased erythropoietin dosing in haemodialysis patients?
    Diskin CJ; Stokes TJ; Dansby LM; Radcliff L; Carter TB
    Nephrology (Carlton); 2006 Oct; 11(5):394-9. PubMed ID: 17014551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of recombinant human erythropoietin (EPO) to correct the anemia of end-stage renal disease: a progress report.
    Adamson W; Egrie JC; Browne JK; Downing MR; Eschbach W
    Behring Inst Mitt; 1988 Aug; (83):188-92. PubMed ID: 3071336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum erythropoietin levels and their correlation with the erythropoietic system in hemodialysis patients and renal allograft recipients.
    Khosroshahi HT; Shoja MM; Tubbs RS; Estakhri R; Ardalan MR
    Transplant Proc; 2007 May; 39(4):1051-3. PubMed ID: 17524889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial hematologic effects of daily oral ascorbic acid therapy in ESRD patients with anemia and abnormal iron homeostasis: a preliminary study.
    Sirover WD; Siddiqui AA; Benz RL
    Ren Fail; 2008; 30(9):884-9. PubMed ID: 18925528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
    Li H; Wang SX
    Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of recombinant human erythropoietin on hospitalization of hemodialysis patients.
    Churchill DN; Muirhead N; Goldstein M; Posen G; Fay W; Beecroft ML; Gorman J; Taylor DW
    Clin Nephrol; 1995 Mar; 43(3):184-8. PubMed ID: 7774076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of hepatitis C infection on anemia in hemodialysis patients.
    Khurana A; Nickel AE; Narayanan M; Foulks CJ
    Hemodial Int; 2008 Jan; 12(1):94-9. PubMed ID: 18271849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of quarterly average achieved hematocrit with mortality in dialysis patients: a time-dependent comorbidity-adjusted model.
    Messana JM; Chuang CC; Turenne M; Wheeler J; Turner J; Sleeman K; Tedeschi P; Hirth R
    Am J Kidney Dis; 2009 Mar; 53(3):503-12. PubMed ID: 19185402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of renal anemia with intravenous erythropoietin in patients in the program of continuous ambulatory peritoneal dialysis].
    Zelichowski G; Lubas A; Sienkiewicz M; Janusz E; Wańkowicz Z
    Pol Merkur Lekarski; 2008 Apr; 24(142):312-5. PubMed ID: 18634362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated therapies including erythropoietin decrease the incidence of dialysis: lessons from mapping the incidence of end-stage renal disease in Japan.
    Furumatsu Y; Nagasawa Y; Hamano T; Iwatani H; Iio K; Shoji T; Ito T; Tsubakihara Y; Imai E
    Nephrol Dial Transplant; 2008 Mar; 23(3):984-90. PubMed ID: 17956890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chronic inflammation, oxidative stress and effects of erythropoetin in end-stage renal disease patients].
    Lazarević T; Stojimirović B; Poskurica M; Lazarević M; Mitrović N; Stolić R
    Med Pregl; 2007; 60 Suppl 2():109-13. PubMed ID: 18928173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble P-selectin during a single hemodialysis session in patients with chronic renal failure and erythropoietin treatment.
    Stasko J; Galajda P; Ivanková J; Hollý P; Rozborilová E; Kubisz P
    Clin Appl Thromb Hemost; 2007 Oct; 13(4):410-5. PubMed ID: 17911193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term erythropoietin therapy does not affect metalloproteinases and their inhibitor levels, oxidative stress and inflammation in hemodialyzed patients.
    Pawlak K; Pawlak D; Mysliwiec M
    Am J Nephrol; 2007; 27(3):221-5. PubMed ID: 17384500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.